May 2, 2017 / 8:58 PM / 3 months ago

BRIEF-UK Drug Tariff rejects current Woulgan application

May 2 (Reuters) - Biotec Pharmacon Asa:

* UK Drug Tariff rejects current Woulgan application

* Subsidiary Biotec Betaglucan has received negative feedback from uk drug tariff regarding application for reimbursement

* management are considering if there are grounds for an appeal in line with NHS' own guidelines

* UK Drug Tariff informed co that nhs has decided not to list woulgan because they consider evidence provided to be insufficient to document cost effectiveness Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below